Latest CDP323 Stories
-- Results Confirm Favorable Safety Profile of Two High Doses of Aramchol -- TEL AVIV, Israel, Dec. 1, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
Biogen Idec (NASDAQ: BIIB) today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA).
MELBOURNE, Australia, Feb.5 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has successfully concluded dose-escalation in its oral Phase I study for CYT997, the company's anticancer vascular-disrupting agent (VDA). The primary objectives of this safety and tolerability study have been achieved.
CAMBRIDGE, Mass., Oct. 28 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced today that President & CEO Thomas P.
Biogen Idec (NASDAQ: BIIB) today announced the publication of Phase IIb data showing that a 240 mg three-times-daily dose of the company's novel oral compound, BG-12 (BG00012, dimethyl fumarate), reduced the number of new gadolinium enhancing (Gd+) lesions by 69 percent in patients with relapsing-remitting
Biogen Idec (NASDAQ: BIIB) announced today that its Phase II trial of baminercept (BG9924, LT(beta)R-Ig) in rheumatoid arthritis (RA) patients who have had an inadequate response to conventional therapy with a disease-modifying antirheumatic drug (DMARD) did not meet its primary endpoint.
CAMBRIDGE, Mass., Sept. 16 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced today that Dr.
US-based biopharmaceutical company XenoPort has announced plans to initiate an exploratory Phase II clinical trial of XP19986 in patients with acute back spasms, which is a debilitating condition affecting approximately two-thirds of patients experiencing lower back pain.
- A person in a secondary role, specifically the second most important character (after the protagonist).